Biohaven’s (BHVN) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Biohaven (NYSE:BHVNFree Report) in a research report released on Wednesday, Benzinga reports.

A number of other research firms also recently weighed in on BHVN. TD Cowen raised their price target on Biohaven from $35.00 to $55.00 and gave the company an outperform rating in a research note on Friday, March 1st. HC Wainwright raised their price objective on Biohaven from $50.00 to $63.00 and gave the company a buy rating in a research report on Monday, March 4th. UBS Group initiated coverage on Biohaven in a research report on Tuesday, February 6th. They issued a buy rating and a $59.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on Biohaven from $32.00 to $56.00 and gave the company an overweight rating in a research report on Friday, February 23rd. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Biohaven currently has an average rating of Buy and a consensus price target of $52.00.

Read Our Latest Stock Analysis on Biohaven

Biohaven Stock Performance

NYSE:BHVN opened at $53.08 on Wednesday. The stock has a 50-day simple moving average of $52.31 and a 200 day simple moving average of $40.67. The company has a market cap of $4.33 billion, a PE ratio of -9.38 and a beta of 1.18. Biohaven has a 52-week low of $12.35 and a 52-week high of $62.21.

Biohaven (NYSE:BHVNGet Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). On average, research analysts predict that Biohaven will post -5.85 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

Hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE lifted its holdings in Biohaven by 19.1% during the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock worth $70,000 after purchasing an additional 94 shares during the last quarter. KBC Group NV acquired a new stake in Biohaven during the 4th quarter worth approximately $74,000. Advisor Group Holdings Inc. lifted its holdings in Biohaven by 219.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 8,606 shares of the company’s stock worth $120,000 after purchasing an additional 5,915 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Biohaven during the 1st quarter worth approximately $143,000. Finally, Creative Planning acquired a new stake in Biohaven during the 4th quarter worth approximately $147,000. 88.78% of the stock is owned by institutional investors and hedge funds.

About Biohaven

(Get Free Report)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

Featured Stories

Analyst Recommendations for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.